FNB Bancorp (FNBG) At $36.42 Forms Top; 6 Analysts Covering Tandem Diabetes Care, Inc. (TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Logo

Among 11 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 6 have Buy rating, 1 Sell and 4 Hold. Therefore 55% are positive. Tandem Diabetes Care had 25 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush maintained the shares of TNDM in report on Wednesday, November 2 with “Outperform” rating. The firm has “Buy” rating by Zacks given on Friday, August 28. On Wednesday, November 2 the stock rating was downgraded by Feltl & Co to “Buy”. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) earned “Neutral” rating by Bank of America on Thursday, January 14. As per Friday, September 4, the company rating was downgraded by Zacks. Stifel Nicolaus downgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rating on Wednesday, November 2. Stifel Nicolaus has “Hold” rating and $3.50 target. The firm has “Hold” rating by Robert W. Baird given on Friday, November 17. Cowen & Co upgraded Tandem Diabetes Care, Inc. (NASDAQ:TNDM) on Wednesday, March 28 to “Buy” rating. The firm earned “Buy” rating on Monday, August 10 by Deutsche Bank. Piper Jaffray downgraded the shares of TNDM in report on Thursday, November 3 to “Neutral” rating. See Tandem Diabetes Care, Inc. (NASDAQ:TNDM) latest ratings:

28/03/2018 Broker: Cowen & Co Rating: Buy New Target: $7.0000 Upgrade
23/03/2018 Broker: Robert W. Baird Old Rating: Neutral New Rating: Outperform Upgrade
02/03/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $4.0 Maintain
27/02/2018 Broker: Cowen & Co Rating: Hold New Target: $5.0 Maintain
27/02/2018 Broker: Oppenheimer Rating: Outperform New Target: $5.5 Initiates Coverage On
20/11/2017 Broker: Bank of America Rating: Underperform Old Target: $20 New Target: $2 Maintain
17/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $3.0 Maintain

FNB Bancorp (FNBG) formed multiple top with $39.33 target or 8.00% above today’s $36.42 share price. FNB Bancorp (FNBG) has $272.90 million valuation. The stock decreased 0.33% or $0.12 during the last trading session, reaching $36.42. About 5 shares traded. FNB Bancorp (NASDAQ:FNBG) has risen 47.98% since May 2, 2017 and is uptrending. It has outperformed by 36.43% the S&P500.

Investors sentiment decreased to 2.5 in Q4 2017. Its down 0.61, from 3.11 in 2017Q3. It fall, as 7 investors sold FNB Bancorp shares while 5 reduced holdings. 12 funds opened positions while 18 raised stakes. 1.28 million shares or 58.61% less from 3.10 million shares in 2017Q3 were reported. Parallax Volatility Advisers Ltd Partnership holds 0% or 1,596 shares. Raymond James & Associate stated it has 22,029 shares. Gru Inc reported 3,573 shares. Tiaa Cref Invest Mgmt Lc holds 0% in FNB Bancorp (NASDAQ:FNBG) or 13,027 shares. Bank & Trust Of New York Mellon accumulated 22,269 shares. Tower Research Cap Ltd (Trc) holds 0.01% or 1,783 shares. Bnp Paribas Arbitrage holds 1,301 shares or 0% of its portfolio. Panagora Asset Mgmt Inc holds 0% or 10,264 shares in its portfolio. Jpmorgan Chase holds 0% of its portfolio in FNB Bancorp (NASDAQ:FNBG) for 1,145 shares. Moreover, First Quadrant Ltd Partnership Ca has 0% invested in FNB Bancorp (NASDAQ:FNBG). Wells Fargo Mn has 0% invested in FNB Bancorp (NASDAQ:FNBG) for 19,943 shares. Acadian Asset Management Ltd Liability Company holds 0% or 13,078 shares in its portfolio. Meeder Asset Management Inc holds 0% or 359 shares in its portfolio. Royal Natl Bank Of Canada has 220 shares for 0% of their portfolio. Strs Ohio owns 500 shares.

The stock increased 1.28% or $0.1 during the last trading session, reaching $7.89. About 154,147 shares traded. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has declined 63.92% since May 2, 2017 and is downtrending. It has underperformed by 75.47% the S&P500.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $395.04 million. The companyÂ’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

FNB Bancorp (NASDAQ:FNBG) Institutional Positions Chart